8-aminoquinoline

antimalarial; sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog

Also Known As:

8-((6-(diethylamino)hexyl)amino)-6-methoxy-4-methylquinoline; 8-(6-diethylaminohexylamino)-6-methoxy-4-methylquinoline dihydrochloride; 8-quinolinamine; N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinolinyl)-1,6- hexanediamine; WR 006026; WR 6026; WR-006026; WR-6026; WR006026; WR6026; sitamaquine

Networked: 103 relevant articles (12 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Aminoquinolines: 29
        8-aminoquinoline: 103

Experts

1.	White, Nicholas J: 8 articles (01/2021 - 10/2011)
2.	Bancone, Germana: 7 articles (01/2018 - 03/2013)
3.	Tekwani, Babu L: 5 articles (09/2021 - 12/2006)
4.	Baird, J Kevin: 5 articles (01/2021 - 03/2003)
5.	Imwong, Mallika: 5 articles (01/2021 - 01/2012)
6.	von Seidlein, Lorenz: 5 articles (01/2020 - 03/2013)
7.	Walker, Larry A: 5 articles (08/2018 - 12/2006)
8.	Dondorp, Arjen M: 4 articles (01/2021 - 03/2016)
9.	Castanys, Santiago: 4 articles (09/2011 - 12/2010)
10.	Gamarro, Francisco: 4 articles (09/2011 - 12/2010)

Related Diseases

1.	Visceral Leishmaniasis (Kala Azar) 12/01/2001 - "WR6026 demonstrated the unusual clinical features of lack of increased efficacy against Brazilian kala-azar with increased dosing above 2 mg/kg/day and toxicity that was not present in previous investigations." 06/01/2011 - "This randomized, open-label study of patients in India with visceral leishmaniasis (VL) investigated the effect of food on sitamaquine and desethyl-sitamaquine pharmacokinetics. " 12/01/2005 - "A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India." 11/01/2005 - "A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya." 06/01/2011 - "Sitamaquine can be taken regardless of food intake, was generally well tolerated, and showed potential efficacy in patients with visceral leishmaniasis."
2.	Vivax Malaria 01/01/2020 - "Radical cure with an 8-aminoquinoline will be needed for the rapid elimination of vivax malaria." 08/01/2004 - "The observation that none of the four test subjects in this study had relapses has not previously been published and may have important implications for the evaluation of other 8-aminoquinoline compounds against relapsing vivax malaria." 01/01/2022 - "Relapses significantly contribute to the vivax malaria burden and are only killed with drugs of the 8-aminoquinoline class, which are contraindicated in many vulnerable populations. " 04/27/2023 - "G6PD deficiency is one of the most common enzymopathies worldwide; therefore, the WHO recommends routine testing to guide 8-aminoquinoline based treatment for vivax malaria whenever possible. " 12/30/2019 - "Adding 8-aminoquinoline to the treatment of falciparum, in addition to vivax malaria, in locations where infections with both species are prevalent could prevent vivax reactivation. "
3.	Cutaneous Leishmaniasis 08/01/2006 - "In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis." 08/01/2006 - "The efficacy of topical formulations of the 8-aminoquinoline, sitamaquine dihydrochloride, in both in-vitro and in in-vivo models of cutaneous leishmaniasis is reported. " 08/01/2006 - "A range of topical sitamaquine dihydrochloride formulations (anhydrous gel, emulsions) were developed for studies on experimental cutaneous leishmaniasis using only topically acceptable excipients or those currently undergoing regulatory approval. " 05/01/2011 - "Sitamaquine is a 8-aminoquinoline in development for the treatment of visceral leishmaniasis by oral route, no activity being observed on the experimental cutaneous leishmaniasis experimental models. " 12/01/2002 - "The results of clinical trials of two oral compounds are reported - fluconazole in treating cutaneous leishmaniasis was found to be safe and effective, whereas sitamaquine (WR6026) for visceral leishmaniasis was found to be toxic with poor efficacy. "
4.	Glucosephosphate Dehydrogenase Deficiency 08/01/2022 - "Therefore, G6PD deficiency testing should precede hypnozoite elimination with 8-aminoquinoline. " 01/01/2020 - "As in many countries the national treatment guidelines recommend 8-aminoquinoline based radical cure without routine G6PD deficiency (G6PDd) testing to guide treatment. " 03/27/2013 - "Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report." 04/27/2023 - "G6PD deficiency is one of the most common enzymopathies worldwide; therefore, the WHO recommends routine testing to guide 8-aminoquinoline based treatment for vivax malaria whenever possible. " 12/30/2019 - "vivax infections, the prevalence and severity of G6PD deficiency in the population and the feasibility to administer 8-aminoquinoline regimens safely. "
5.	Infections 12/01/2006 - "This review focuses on recent developments on evaluation of 8-aminoquinoline analogs with broader efficacy and reduced toxicity, which would provide better drugs for treatment of protozoal infections. " 11/01/1977 - "Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose." 12/30/2019 - "vivax infections, the prevalence and severity of G6PD deficiency in the population and the feasibility to administer 8-aminoquinoline regimens safely. " 12/30/2019 - "Adding 8-aminoquinoline to the treatment of falciparum, in addition to vivax malaria, in locations where infections with both species are prevalent could prevent vivax reactivation. " 03/24/2016 - "vivax infections by 8-aminoquinoline regimens may be required to eliminate all malaria from Cambodia. "

Related Drugs and Biologics

1.	8-aminoquinoline
2.	Primaquine
3.	Fluconazole (Zonal)
4.	tafenoquine
5.	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)
6.	Chloroquine (Aralen)
7.	Succinic Acid (Succinate)
8.	Triazines
9.	Chlorine
10.	quinoline

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Chemoprevention